Analysts expect Stryker Co. (NYSE:SYK) to post $3.27 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Stryker’s earnings, with estimates ranging from $3.24 billion to $3.30 billion. Stryker reported sales of $3.01 billion in the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The company is scheduled to announce its next earnings report on Thursday, October 25th.
On average, analysts expect that Stryker will report full-year sales of $13.54 billion for the current year, with estimates ranging from $13.46 billion to $13.64 billion. For the next financial year, analysts anticipate that the business will post sales of $14.40 billion per share, with estimates ranging from $14.30 billion to $14.56 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Stryker.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.03. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The company had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.31 billion. During the same period in the prior year, the firm posted $1.53 EPS. Stryker’s revenue for the quarter was up 10.3% on a year-over-year basis.
A number of analysts have recently issued reports on SYK shares. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Canaccord Genuity reaffirmed a “buy” rating and set a $185.00 price target on shares of Stryker in a report on Wednesday, July 25th. Royal Bank of Canada reaffirmed a “buy” rating and set a $184.00 price target on shares of Stryker in a report on Wednesday, July 25th. Zacks Investment Research downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, May 24th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $170.00 price target on shares of Stryker in a report on Wednesday, June 13th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $176.15.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $166.42, for a total value of $832,100.00. Following the transaction, the insider now owns 101,675 shares in the company, valued at approximately $16,920,753.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Stryker by 2.0% during the 1st quarter. BlackRock Inc. now owns 23,905,172 shares of the medical technology company’s stock valued at $3,846,819,000 after buying an additional 458,485 shares in the last quarter. Carmignac Gestion grew its holdings in Stryker by 36.6% during the 1st quarter. Carmignac Gestion now owns 1,599,867 shares of the medical technology company’s stock valued at $257,451,000 after buying an additional 428,789 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Stryker by 2.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 1,198,702 shares of the medical technology company’s stock valued at $192,896,000 after buying an additional 31,950 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Stryker by 1.0% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,031,481 shares of the medical technology company’s stock valued at $165,986,000 after buying an additional 10,062 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Stryker by 49.4% during the 1st quarter. Royal Bank of Canada now owns 889,975 shares of the medical technology company’s stock valued at $143,214,000 after buying an additional 294,276 shares in the last quarter. Institutional investors own 74.77% of the company’s stock.
Shares of Stryker traded down $3.78, reaching $165.26, during trading on Friday, according to MarketBeat Ratings. 77,004 shares of the company traded hands, compared to its average volume of 923,160. The company has a quick ratio of 1.15, a current ratio of 1.83 and a debt-to-equity ratio of 0.63. The company has a market cap of $63.22 billion, a PE ratio of 25.90, a PEG ratio of 2.40 and a beta of 0.70. Stryker has a 52-week low of $137.70 and a 52-week high of $179.84.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.14%. The ex-dividend date of this dividend is Thursday, June 28th. Stryker’s dividend payout ratio (DPR) is presently 28.97%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.